Matrubials ^Company

Matrubials Inc. is developing novel antibacterial therapeutics to address non-selectivity and emerging antimicrobial resistance. The company's mission is to provide safe solutions that can reduce the healthcare and economic burden resulting from bacterial infections and concomitant clinical complications. Its first indication is Bacterial Vaginosis (BV), which impacts almost a third of all women. It is a type of inflammation that results in recurrent infections, disruption of homeostasis and longer-term complications in women of reproductive ages. These include but are not limited to urinary tract and yeast infections, miscarriages and preterm births, fertility issues, pelvic inflammatory disease and increased rates of STDs. They are leading efforts to address BV via topical therapeutics.